Northern Trust’s Vivos Therapeutics VVOS Stock Holding History

Northern Trust’s Portfolio VVOS Stock Details VVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.44K	Buy	20,775 +8,264	+66%	+$6.48K	﹤0.01%	4415
2026 Q1	$14.8K	Hold	12,511	–	–	﹤0.01%	4353
2025 Q4	$25.4K	Hold	12,511	–	–	﹤0.01%	4370
2025 Q3	$38.8K	Hold	12,511	–	–	﹤0.01%	4315
2025 Q2	$39.5K	Hold	12,511	–	–	﹤0.01%	4271
2025 Q1	$35.7K	Buy	+12,511	New	+$49.1K	﹤0.01%	4281
2023 Q4	–	Sell	-1,186	Closed	-$5.7K	–	4552
2023 Q3	$5.7K	Hold	1,186	–	–	﹤0.01%	4428
2023 Q2	$15.1K	Hold	1,186	–	–	﹤0.01%	4444
2023 Q1	$10.1K	Hold	1,186	–	–	﹤0.01%	4524
2022 Q4	$11.9K	Hold	1,186	–	–	﹤0.01%	4558
2022 Q3	$19K	Sell	1,186 -445	-27%	-$13.6K	﹤0.01%	4556
2022 Q2	$52K	Hold	1,631	–	–	﹤0.01%	4405
2022 Q1	$109K	Buy	1,631 +7	+0.4%	+$458	﹤0.01%	4319
2021 Q4	$91K	Sell	1,624 -17	-1%	-$1.37K	﹤0.01%	4451
2021 Q3	$166K	Buy	1,641 +1,182	+258%	+$124K	﹤0.01%	4254
2021 Q2	$57K	Buy	+459	New	+$74.8K	﹤0.01%	4472

Other funds holding VVOS

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

CWM

Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

Northern Trust's VVOS Position: Q2 2026 in Review

Northern Trust increased its Vivos Therapeutics (VVOS) stake by 66% in Q2 2026, buying an estimated $6.48K and bringing the position to 20,775 shares worth $9.44K. The position accounts for ﹤0.01% of the portfolio, ranked #4415.

Northern Trust first reported a position in VVOS in Q2 2021 and has held it in 16 quarters since. The position peaked at $166K in Q3 2021. 23 funds tracked by Wall St. Rank hold VVOS as of Q2 2026.

Northern Trust held 20,775 shares of Vivos Therapeutics worth $9.44K as of Q2 2026.
Northern Trust bought 8,264 Vivos Therapeutics shares in Q2 2026, an estimated $6.48K.
Vivos Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #4415 holding.
Northern Trust first reported a position in Vivos Therapeutics in Q2 2021 and has held it in 16 quarters since.
Northern Trust's Vivos Therapeutics position peaked at $166K in Q3 2021.
23 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.